Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.62 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.58 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.58 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.58 |
| ▸ | CHRNB3 | Q05901 | 3/20 | 0.58 |
| ▸ | CHRNA6 | Q15825 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13097342 | 0.91 | ALDH1A1 (0.71) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL5102657 | 0.89 | HPGD (0.52) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL8518590 | 0.89 | HPGD (0.52) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL7985966 | 0.89 | ALDH1A1 (0.75) | HPGDALDH1A1TSHRSMN1; SMN2HSD11B1 | |
| Hydrochloric Acid SCHEMBL4715501 | 0.88 | HPGD (0.50) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| Hydrochloric Acid SCHEMBL5348833 | 0.88 | HPGD (0.50) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL24341885 | 0.86 | HPGD (0.52) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL26204911 | 0.86 | HPGD (0.78) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL17546310 | 0.85 | HPGD (0.52) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL24312807 | 0.85 | CHRNB2 (0.64) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018030-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| CN-103582638-B | Heteroaryl pyrimidine derivative, preparation method and application thereof | JIANGSU HANSOH PHARMACEUTICAL Co.,Ltd. (CN) | 2016-02-10 | — | — | CN | disclosed |
| CN-103582638-A | Heteroaryl pyrimidine derivative, preparation method and application thereof | JIANGSU HANSON PHARMACEUTICAL CO LTD | 2014-02-12 | — | — | CN | disclosed |
| WO-2013016999-A1 | HETEROARYL-PYRIMIDINE DERIVATIVES, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏豪森药业股份有限公司 (CN) | 2013-02-07 | — | — | WO | disclosed |
| CN-102911172-A | Heteroaryl pyrimidine derivatives and preparation method and application thereof | SHANGHAI HENGRUI MEDICINE CO LTD | 2013-02-06 | — | — | CN | disclosed |
| EP-0367110-B1 | 1,4-diazepine derivative and its pharmaceutical use | EISAI CO LTD (JP) | 1999-08-11 | — | — | EP | disclosed |
| CN-1036520-C | 1,4-diazepine derivative and its pharmaceutical use | EISAI CO LTD (JP) | 1997-11-26 | — | — | CN | disclosed |
| CN-1121076-A | 1,4-diazepine derivative and its pharmaceutical use | EISAI CO LTD (JP) | 1996-04-24 | — | — | CN | disclosed |
| US-5482937-A | ANTIALLERGENS AND PLATELET ACTIVATING FACTOR FOR TREATMENT OF INFLAMMATION | EISAI CO., LTD. (JP) | 1996-01-09 | — | — | US | disclosed |
| US-5468740-A | Anti-platelet activating factor activity; antiallergens, antiasthmatics | EISAI CO., LTD. (JP) | 1995-11-21 | — | — | US | disclosed |
| EP-0677524-A1 | Thieno[3,2-F][1,2,4]triazolo[4,3-A][1,4]diazepine derivatives as PAF antagonists | Eisai Co., Ltd. (JP) | 1995-10-18 | — | — | EP | disclosed |
| US-5438045-A | An 3-acetyl-6-phenyl-2,3,4,5-tetrahydro-8h-pyrido(4'3':4,5)-thieno(3,2 -f)(1,2,4)triazolo(4,3-a)(1,4)diazepine derivative; antiallergens; asthma; antiplatelet activating factor activity | EISAI CO., LTD. (JP) | 1995-08-01 | — | — | US | disclosed |
| CN-1028640-C | 1, 4-diazepine derivatives and their use as herbicides | EISAI CO LTD (JP) | 1995-05-31 | — | — | CN | disclosed |
| US-5409909-A | Antiallergens | EISAI CO., LTD. (JP) | 1995-04-25 | — | — | US | disclosed |
| US-5382579-A | Platelet activating factor antagonists; antiallergens; asthma | EISAI CO., LTD. (JP) | 1995-01-17 | — | — | US | disclosed |
| EP-0606103-A1 | Thieno 3.2-f 1,2,4 triazolo 4,3-a 1,4 -diazepine derivatives as PAF antagonists | Eisai Co., Ltd. (JP) | 1994-07-13 | — | — | EP | disclosed |
| US-5304553-A | Antiallergens; platelet activating factor inhibitor | EISAI CO., LTD. (JP) | 1994-04-19 | — | — | US | disclosed |
| US-5221671-A | Antiallergens, bronchodilator agents | EISAI CO., LTD. (JP) | 1993-06-22 | — | — | US | disclosed |
| CN-1042356-A | 1, 4-diaza * derivatives and their pharmaceutical use | EISAI CO LTD (JP) | 1990-05-23 | — | — | CN | disclosed |
| EP-0367110-A1 | 1,4-diazepine derivative and its pharmaceutical use | Eisai Co., Ltd. (JP) | 1990-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018030-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, UBXN1 | HPGD 3219/4885CHRNB2 4342/4885CHRNA3 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.